Aging represents a complex biological phenomenon marked by the progressive deterioration of physiological functions over time, reduced resilience, and increased vulnerability to age-related diseases, ultimately culminating in mortality. Recent research has uncovered diverse molecular mechanisms through which metformin extends its benefits beyond glycemic control, presenting it as a promising intervention against aging. This review delves into the anti-aging properties of metformin, highlighting its role in mitochondrial energy modulation, activation of the AMPK-mTOR signaling pathway, stimulation of autophagy, and mitigation of inflammation linked to cellular aging. Furthermore, we discuss its influence on epigenetic modifications that underpin genomic stability and cellular homeostasis. Metformin’s potential in addressing age-associated disorders including metabolic, cardiovascular, and neurodegenerative diseases is also explored. The Targeting Aging with Metformin (TAME) trial aims to provide key evidence on its efficacy in delaying aging in humans. Despite these promising insights, significant challenges persist in gaining a more comprehensive understanding into its underlying mechanisms, determining optimal dosing strategies, and evaluating long-term safety in non-diabetic populations. Addressing these challenges is crucial to fully realizing metformin’s potential as an anti-aging therapeutic.
Adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) is an energy homeostasis controller that regulates various metabolic pathways to promote adenosine triphosphate (ATP) generation and suppress energy expenditure, thereby restoring energy homeostasis. As a co-factor in many enzymes, iron is an essential mineral for maintaining ATP levels in our bodies. Ferroptosis is an iron-dependent mode of cell death that occurs in various pathological processes, including cancer, metabolic disorders, and autoimmune diseases, by regulating iron metabolism, lipoperoxidation, and anti-oxidation functions. Ferroptosis is triggered by oxidative and energy stress, both controlled by cancer-associated signaling pathways. Emerging studies have demonstrated that AMPK directly influences ferroptosis by modulating lipid metabolism, redox homeostasis, and iron transport. Cancer cells exhibiting elevated baseline AMPK activity demonstrate resistance to ferroptosis, whereas AMPK suppression enhances their susceptibility to this regulated form of cell death. While the precise mechanistic details are yet to be fully elucidated, accumulating evidence suggests that AMPK-mediated ferroptosis regulation may contribute to cancer development and therapeutic responses. This review summarizes recent advances in understanding the interplay between AMPK and ferroptosis in cancer biology and discusses the potential of targeting the AMPK-ferroptosis axis for innovative anticancer strategies.
The intervertebral disc (IVD) is the largest avascular structure in the human body, and its nucleus pulposus (NP) cells predominantly generate large amounts of lactate through glycolysis, accompanied by an acidic microenvironment—features that represent characteristic metabolic traits of disc cells. In recent years, knowledge of the biological roles of lactate has undergone a conceptual shift. On the one hand, lactate can serve as a context-dependent auxiliary biofuel in specific regions of the IVD, particularly within annulus fibrosus (AF) regions adjacent to the NP. On the other hand, lactate functions in disc cells as a signaling molecule and a metabolic–epigenetic regulator, influencing transcriptional programs through lactylation and modulating multiple molecular pathways associated with cellular stress adaptation and fate determination. This review summarizes current knowledge on lactate production, transport, and clearance in the intervertebral disc, as well as emerging evidence for the roles of lactate in disc health and pathophysiology. In addition, we outline research perspectives and future directions aimed at advancing our understanding of lactate biology and evaluating its potential as a therapeutic target for intervertebral disc degeneration.
The nucleus pulposus (NP) of the intervertebral disc is an immune-privileged tissue. During intervertebral disc degeneration (IDD), this immune privilege is compromised, resulting in the exposure of NP components to the peripheral immune system, which in turn activates monocytes and elicits an immune response. In this study, we demonstrate that monocytes respond to NP immunogenicity by activating damage-associated molecular patterns (DAMPs), thereby initiating a sustained NF-κB-mediated inflammatory response in NP tissue and ultimately driving a vicious cycle of inflammation and oxidative stress within NP cells. Mechanistically, NP-derived immunogenic stimulation induces monocyte activation, accompanied by increased expression and nuclear translocation of the deubiquitinase USP7. USP7 promotes the accumulation and nuclear translocation of the NF-κB subunit p65 via a deubiquitination-dependent mechanism, leading to enhanced transcription of TNF-α, HMGB1, and IL-1β. These DAMP-associated cytokines further stimulate NP cells, resulting in upregulation of HMGB1, TNF-α, COX-2, IL-1β, and reactive oxygen species (ROS), along with a concomitant decrease in the antioxidant enzyme SOD2-collectively amplifying inflammation and oxidative stress within the NP microenvironment. Dual-luciferase reporter assays and chromatin immunoprecipitation (ChIP)-qPCR demonstrated that knockdown of USP7 in monocytes significantly reduced p65 binding to the promoter regions of TNF-α, HMGB1, and IL-1β, thereby attenuating the downstream inflammatory and oxidative stress responses in NP cells. Together, these findings uncover a novel immune-inflammatory mechanism underlying IDD and highlight the USP7-mediated pathway in monocytes as a potential therapeutic target for modulating disc degeneration.
Intervertebral discs are avascular and maintain immune privilege. However, during intervertebral disc degeneration (IDD), this barrier is disrupted, leading to extensive immune cell infiltration and localized inflammation. In degenerated discs, macrophages, T lymphocytes, neutrophils, and granulocytic myeloid-derived suppressor cells (G-MDSCs) are key players, exhibiting functional heterogeneity. Dysregulated activation of inflammatory pathways, including nuclear factor kappa-B (NF-kappaB), interleukin-17 (IL-17), and nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation, drives local pro-inflammatory responses, leading to cell apoptosis and extracellular matrix (ECM) degradation. Innovative immunotherapies, including exosome-based treatments, CRISPR/Cas9-mediated gene editing, and chemokine-loaded hydrogel systems, have shown promise in reshaping the immunological niche of intervertebral discs. These strategies can modulate dysregulated immune responses and create a supportive environment for tissue regeneration. However, current studies have not fully elucidated the mechanisms of inflammatory memory and the immunometabolic axis, and they face challenges in balancing tissue regeneration with immune homeostasis. Future studies should employ interdisciplinary approaches such as single-cell and spatial transcriptomics to map a comprehensive immune atlas of IDD, elucidate intercellular crosstalk and signaling networks, and develop integrated therapies combining targeted immunomodulation with regenerative engineering, thereby facilitating the clinical translation of effective IDD treatments.
Healing of Tendon-bone interface(TBI) injuries is slow and is often repaired with scar tissue formation that compromises normal function. Despite the increasing maturity of surgical techniques, re-tearing of the rotator cuff after surgery remains common. The main reason for this issue is that the original structure of the rotator cuff at the TBI area is difficult to fully restore after surgery, and anatomical healing of the rotator cuff TBI is challenging to achieve solely through surgery. With the advancement of tissue engineering technology, more and more basic researchers and clinical surgeons are recognizing the enormous potential of tissue engineering in promoting TBI healing. Growing research evidence indicates that tissue engineering technology not only effectively promotes repairing and remodeling of the TBI but also reduces the formation of fibrous vascular scar tissue, leading to more orderly tissue reconstruction. The core of tissue engineering technology approaches lies in combining the use of various scaffolds, cells and bioactive molecules to simulate the natural environment of TBI healing, achieving optimal therapeutic outcomes. In this review, we will systematically summarize and highlight recent progress in the application of tissue engineering on TBI regeneration, particularly focusing on advancements in novel scaffolds and their role and potential in promoting healing of the TBI of rotator cuff, providing valuable references for clinical application and research.